Protagenic Therapeutics, Inc.\new Amortization of Debt Discount (Premium)
Protagenic Therapeutics, Inc.\new (PTIX) reported Amortization of Debt Discount (Premium) of $1.57 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-08-19
- Protagenic Therapeutics, Inc.\new amortization of debt discount (premium) for the quarter ending 2026-03-31 was $1.32M, a 635.46% increase year-over-year.
- Protagenic Therapeutics, Inc.\new amortization of debt discount (premium) for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new amortization of debt discount (premium) for the quarter ending 2025-09-30 was $0.00.
- Protagenic Therapeutics, Inc.\new amortization of debt discount (premium) for the quarter ending 2025-06-30 was $243.35K.
- Protagenic Therapeutics, Inc.\new amortization of debt discount (premium) for fiscal 2026 was $1.57M, a 161.77% increase from fiscal 2025.
- Protagenic Therapeutics, Inc.\new amortization of debt discount (premium) for fiscal 2025 was $598.81K.
- Protagenic Therapeutics, Inc.\new amortization of debt discount (premium) for fiscal 2023 was $85.77K, a 22.59% decline from fiscal 2022.
- Protagenic Therapeutics, Inc.\new amortization of debt discount (premium) for fiscal 2022 was $110.80K, a 74.06% decline from fiscal 2021.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2026-03-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-14 | $1.32M derived: sum of 2 quarters · filed 2026-08-14 | $1.32M derived: sum of 3 quarters · filed 2026-08-14 | $1.57M 10-K · filed 2026-08-14 |
| 2025-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $243.35K 10-Q · filed 2026-03-09 | $423.39K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-26 | $243.35K 10-Q · filed 2025-11-26 | $423.39K derived: sum of 3 quarters · filed 2026-08-19 | $603.44K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $243.35K 10-Q · filed 2026-08-19 | $423.39K derived: sum of 2 quarters · filed 2026-08-19 | $603.44K derived: sum of 3 quarters · filed 2026-08-19 | |
| 2025-03-31 | $180.04K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-14 | $360.08K derived: sum of 2 quarters · filed 2026-08-14 | $598.81K 10-K · filed 2026-08-14 | |
| 2024-12-31 | $180.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-09 | $418.77K 10-Q · filed 2026-03-09 | ||
| 2024-09-30 | $238.73K 10-Q · filed 2025-11-26 | |||
| 2023-12-31 | $10.24K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $35.69K derived: sum of 2 quarters · filed 2025-03-31 | $60.87K derived: sum of 3 quarters · filed 2025-03-31 | $85.77K 10-K · filed 2025-03-31 |
| 2023-09-30 | $25.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $50.63K derived: sum of 2 quarters · filed 2024-11-14 | $75.53K 10-Q · filed 2024-11-14 | $100.99K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $25.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $50.08K 10-Q · filed 2024-08-14 | $75.53K derived: sum of 3 quarters · filed 2024-08-14 | $100.99K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $24.90K 10-Q · filed 2024-05-15 | $50.35K derived: sum of 2 quarters · filed 2024-05-15 | $75.81K derived: sum of 3 quarters · filed 2024-05-15 | $109.07K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $25.45K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-05-14 | $50.91K derived: sum of 2 quarters · filed 2024-05-14 | $84.17K derived: sum of 3 quarters · filed 2024-05-14 | $110.80K 10-K/A · filed 2024-05-14 |
| 2022-09-30 | $25.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $58.72K derived: sum of 2 quarters · filed 2023-11-14 | $85.34K 10-Q · filed 2023-11-14 | $134.19K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $33.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $59.89K 10-Q · filed 2023-08-14 | $108.73K derived: sum of 3 quarters · filed 2023-08-14 | $209.41K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $26.63K 10-Q · filed 2023-05-15 | $75.47K derived: sum of 2 quarters · filed 2023-05-15 | $176.15K derived: sum of 3 quarters · filed 2023-05-15 | $399.79K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $48.84K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $149.52K derived: sum of 2 quarters · filed 2023-03-31 | $373.16K derived: sum of 3 quarters · filed 2023-03-31 | $427.14K 10-K · filed 2023-03-31 |
| 2021-09-30 | $100.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $324.32K derived: sum of 2 quarters · filed 2022-11-14 | $378.29K 10-Q · filed 2022-11-14 | $429.02K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $223.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $277.62K 10-Q · filed 2022-08-11 | $328.35K derived: sum of 3 quarters · filed 2022-08-11 | $373.60K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $53.98K 10-Q · filed 2022-05-13 | $104.70K derived: sum of 2 quarters · filed 2022-05-13 | $149.95K derived: sum of 3 quarters · filed 2022-05-13 | $181.52K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $50.73K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-07 | $95.98K derived: sum of 2 quarters · filed 2022-04-07 | $127.54K derived: sum of 3 quarters · filed 2022-04-07 | $154.90K 10-K · filed 2022-04-07 |
| 2020-09-30 | $45.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $76.81K derived: sum of 2 quarters · filed 2021-11-15 | $104.17K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $31.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $58.92K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $27.36K 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $11.37K 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |